Asia Pacific Non Small Cell Lung Cancer Diagnostics Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2021 –2028 |
 حجم السوق (السنة الأساسية) |
USD 291.14 Million |
 حجم السوق (سنة التنبؤ) |
USD 865.62 Million |
 CAGR |
% |
| Major Markets Players |
سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة في منطقة آسيا والمحيط الهادئ، حسب نوع السرطان (سرطان الغدة الرئوية (LUAD)، سرطان الخلايا الحرشفية في الرئة (LUSC)، سرطان الخلايا الكبيرة وغيرها)، المنتج (الكواشف والمجموعات، الأدوات والخدمات والبرمجيات) الاختبار (اختبار التصوير، الاختبار الجزيئي، الخزعة، علم الخلايا البلغمية، بزل الصدر، المناعة الكيميائية، وغيرها)، المستخدم النهائي (المستشفيات والمختبرات السريرية والأكاديميون وغيرهم) الدولة (الصين وتايلاند وأستراليا واليابان وكوريا الجنوبية وسنغافورة وماليزيا وإندونيسيا والفلبين والهند وبقية دول آسيا والمحيط الهادئ) اتجاهات الصناعة والتوقعات حتى عام 2028.
تحليل السوق والرؤى: سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة في منطقة آسيا والمحيط الهادئ
من المتوقع أن يصل سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة في منطقة آسيا والمحيط الهادئ إلى 865.62 مليون دولار أمريكي بحلول عام 2028 من 291.14 مليون دولار أمريكي في عام 2020، بمعدل نمو سنوي مركب ثابت قدره 14.6٪ في الفترة المتوقعة من 2021 إلى 2028.
سرطان الرئة ذو الخلايا غير الصغيرة هو مرض تتشكل فيه خلايا خبيثة أو خلايا سرطانية في أنسجة الرئتين. وتختلف هذه الخلايا من حيث النوع، ولكل نوع خلايا سرطانية مختلفة تنمو وتنتشر بطرق معينة. وأنواع سرطان الرئة ذو الخلايا غير الصغيرة هي سرطان الخلايا الحرشفية، وسرطان الخلايا الكبيرة، وسرطان الغدد. وفي سرطان الخلايا الحرشفية، يتشكل السرطان في الخلايا الرقيقة المسطحة التي تبطن داخل الرئتين ويسمى سرطان البشرة. ويبدأ سرطان الخلايا الكبيرة في عدة أنواع من الخلايا الكبيرة. ويبدأ سرطان الغدد في الخلايا التي تبطن الحويصلات الهوائية وتصنع مواد مثل المخاط. ومن المخاطر الكبيرة لسرطان الرئة ذو الخلايا غير الصغيرة التدخين والأعراض التي تشمل السعال الذي لا يزول وضيق التنفس. وتستخدم اختبارات مختلفة، مثل اختبارات التصوير والاختبارات الجزيئية والخزعات وغيرها، لتشخيص وفحص مرحلة السرطان. يعد التشخيص ضروريًا لتحديد المرض في الوقت المناسب حتى يمكن إعطاء العلاج المناسب للمرضى.
العوامل التي تدفع نمو سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة هي استخدام الذكاء الاصطناعي والتعلم الآلي لتحسين إجراءات التشخيص إلى جانب ارتفاع عدد السكان المسنين الأكثر عرضة للإصابة بسرطان الرئة ذو الخلايا غير الصغيرة في حين أن المنافسة العالية في السوق وسلسلة التوريد المضطربة بسبب جائحة COVID-19 قد تشكل تحديًا لنمو سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة.
Moreover, the rise in healthcare expenditure in developing countries and the increase in the adoption of new technology to diagnose non-small cell lung cancer will create huge opportunities for the global non-small cell lung cancer diagnostics market. On the other hand, high competition in the market and disturbed supply chain due to the COVID-19 pandemic are expected to challenge the global non-small cell lung cancer diagnostics market.
The non-small cell lung cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the non-small cell lung cancer diagnostics market scenario, contact Data Bridge Market Research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market Scope and Market Size
The Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing number of adenocarcinoma lung cancer patients in the world.
- On the basis of products, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. In 2021, the instrument is expected to dominate the non-small cell lung cancer diagnostics market due to the increasing demand for high technological instruments to diagnose non-small cell lung cancer with accuracy.
- On the basis of the test, the Asia-Pacific non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing need for molecular tests for lung cancer diagnosis to provide proper treatment to patients.
- On the basis of end-user, the Asia-Pacific non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academics, and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the increase in research on non-small cell lung cancer in clinical laboratories.
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis
Asia-Pacific non-small cell lung cancer diagnostics market is segmented into four notable segments based on the cancer type, products, test, and end-user.
Countries covered in the Asia-Pacific Non-small cell lung cancer diagnostics market report are China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and the Rest of Asia-Pacific.
The products segment in the China region is expected to grow with the highest share in the forecast period of 2021 to 2028 because of the increase in demand for diagnosis instruments to diagnose non-small cell lung cancer patients. The products segment in India is dominating the Asia-Pacific market owing to increased healthcare expenditure. The Philippines is leading the growth of the Asia-Pacific market for products segment is dominating in this country due to rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities By Major Market Players To Enhance The Awareness For Non-Small Cell Lung Cancer Diagnostics, Is Boosting The Market Growth Of Non-Small Cell Lung Cancer Diagnostics Market.
The non-small cell lung cancer diagnostics market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players' strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Asia-Pacific Non-small cell lung cancer diagnostics Market Share Analysis
يوفر المشهد التنافسي لسوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة في منطقة آسيا والمحيط الهادئ تفاصيل عن كل منافس. تتضمن التفاصيل نظرة عامة على الشركة، والمالية، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والتواجد في الهند، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف للشركة، وإطلاق المنتج، وخطوط أنابيب تجارب المنتجات، وموافقات المنتجات، وبراءات الاختراع، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة.
بعض اللاعبين الرئيسيين العاملين في سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة هم Abbott Laboratories و F. Hoffmann-La Roche Ltd و Agilent Technologies, Inc. و QIAGEN و Thermo Fisher Scientific Inc. و Quest Diagnostics Incorporated و NeoGenomics Laboratories, Inc. و NanoString و Janssen Pharmaceutical NV و Inivata Ltd و bioMérieux SA و Biotheranostics و OncoCyte Corporation Inc. و GENERAL ELECTRIC COMPANY و Eckert & Ziegler و Dr. Lal PathLabs و RIVERAIN TECHNOLOGIES و PlexBio Co., Ltd و Oncimmune و Biodesix. من بين اللاعبين المحليين الآخرين. يفهم محللو DBMR نقاط القوة التنافسية ويوفرون تحليلًا تنافسيًا لكل منافس على حدة.
كما يتم أيضًا إطلاق العديد من العقود والاتفاقيات والإطلاقات من قبل شركات حول العالم، مما يعمل أيضًا على تسريع سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة.
على سبيل المثال،
- في مارس 2021، استحوذت شركة Agilent Technologies, Inc. على شركة Resolution Bioscience مقابل 550 مليون دولار أمريكي لتعزيز أعمالها في حلول الأورام القائمة على التسلسل الجيني من الجيل التالي (NGS)
- في مايو 2021، أطلقت شركة QIAGEN مجموعة Therascreen KRAS RGQ PCR المعتمدة من إدارة الغذاء والدواء الأمريكية، والتي تساعد في التعرف على سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC) لدى المرضى
- في يونيو 2020، أطلقت شركة F. Hoffmann-La Roche Ltd خوارزمية علم الأمراض الرقمية الآلية، تحليل الصور uPath PD-L1 (SP263)، لتشخيص سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC) وتحسين سرعة ودقة العلاج التشخيصي
إن التعاون وإطلاق المنتج وتوسيع الأعمال والجوائز والتقدير والمشاريع المشتركة وغيرها من الاستراتيجيات التي يتبعها اللاعب في السوق تعمل على تعزيز بصمات الشركة في سوق تشخيص سرطان الرئة ذو الخلايا غير الصغيرة، مما يوفر أيضًا فائدة لنمو أرباح المنظمة.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 CANCER TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
4.2 PRODUCT AND BRAND ANALYSIS: ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
4.3 ABBOTT LABORATORIES-
4.4 F. HOFFMANN-LA ROCHE LTD -
4.5 AGILENT TECHNOLOGIES, INC.
4.6 QIAGEN
4.7 THERMO FISHER SCIENTIFIC, INC
4.8 QUEST DIAGNOSTICS INCORPORATED
4.9 NEOGENOMICS LABORATORIES, INC.
4.1 NANOSTRING
4.11 JANSSEN PHARMACEUTICAL NV
4.12 INIVATA LTD
4.13 BIOMÉRIEUX SA
4.14 BIOTHERANOSTICS, INC.
4.15 ONCOCYTE CORPORATION
4.16 ECKERT & ZIEGLER
4.17 GENERAL ELECTRIC COMPANY
4.18 DR LAL PATHLABS
4.19 RIVERAIN TECHNOLOGIES
4.2 PLEXBIO CO.,LTD
4.21 BIODESIX
4.22 ONCIMMUNE
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF LUNG CANCER ACROSS THE WORLD
5.1.2 GROWING NUMBER OF GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER
5.1.3 GROWING COLLABORATION PARTNERSHIP AND AGREEMENT BY THE KEY PLAYERS
5.1.4 GROWING USAGE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO IMPROVE THE DIAGNOSTIC PROCEDURES
5.1.5 INCREASING PREVALENCE OF UNHEALTHY LIFESTYLE THAT POSES A SERIOUS RISK OF LUNG CANCER
5.1.6 GROWING PRODUCT LAUNCHES
5.2 RESTRAINTS
5.2.1 CHALLENGES ASSOCIATED WITH BRAND EQUITY
5.2.2 MAINTAINING HIGH LEVEL OF EXPERTISE FOR DIAGNOSIS PURPOSE
5.3 OPPORTUNITIES
5.3.1 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
5.3.2 INCREASING ADOPTION OF NEW TECHNOLOGY TO DIAGNOSE NON-SMALL CELL LUNG CANCER
5.3.3 INCREASE IN THE NUMBER OF APPROVALS FOR NON-SMALL CELL LUNG CANCER PRODUCTS
5.4 CHALLENGES
5.4.1 HIGH COMPETITION AMONG MARKET PLAYERS
5.4.2 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE ASIA-PACIFIC NON SMALL CELL LUNG CANCER DIAGNOSTIC MARKET
6.1 IMPACT ON DEMAND
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON PRICE
6.4 CONCLUSION
7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE
7.1 OVERVIEW
7.2 LUNG ADENOCARCINOMA (LUAD)
7.3 LUNG SQUAMOUS CELL CARCINOMA (LUSC)
7.4 LARGE CELL CARCINOMA
7.5 OTHERS
8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 REAGENTS AND KITS
8.3.1 LUNG CANCER ASSAY KIT
8.3.2 MUTATION KIT
8.3.3 EXTRACTION KIT
8.3.4 SAMPLE PREPARATION KIT
8.3.5 SOLID TUMOUR KIT
8.3.6 OTHERS
8.4 SERVICES AND SOFTWARES
9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST
9.1 OVERVIEW
9.2 MOLECULAR TEST
9.2.1 RT-PCR
9.2.2 NEXT-GENERATION SEQUENCING (NGS)
9.2.3 DNA MICROARRAY
9.2.4 NEXT GENERATION CAPTURE
9.2.5 LAB-ON -A CHIP (LOAC)
9.2.6 MULTIPLEX CONVENTIONAL
9.2.7 PROTEIN MICROARRAY
9.2.8 OTHER
9.3 IMAGING TEST
9.3.1 PISITRON EMISSION TOMOGRAPHY (PET) SCAN
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) SCAN
9.3.3 CT SCAN
9.3.4 BONE SCAN
9.3.5 OTHERS
9.4 IMMUNOHISTOCHEMISTRY
9.5 BIOPSY
9.6 SPUTUM CYTOLOGY
9.7 THORECENTESIS
9.8 OTHERS
10 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
10.5 INSTITUTES AND RESEARCH CENTERS
11 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 SOUTH KOREA
11.1.5 AUSTRALIA
11.1.6 MALAYSIA
11.1.7 THAILAND
11.1.8 INDONESIA
11.1.9 SINGAPORE
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 QUEST DIAGNOSTICS INCORPORATED
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 GENERAL ELECTRIC COMPANY
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NANOSTRING
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BIODESIX
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BIOMERIEUX SA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 BIOTHERANOSTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DR LAL PATHLABS
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 ECKERT & ZIEGLER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 INIVATA LTD
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JANSSEN PHARMACEUTICAL NV
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 NEOGENOMICS LABORATORIES, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 ONCIMMUNE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 ONCOCYTE CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 PLEXIBIO CO LTD
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 RIVERAIN TECHNOLOGIES
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 AGING WORLD POPULATION
TABLE 2 U.K. X RAY DEMAND 2018
TABLE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC LUNG ADENOCARCINOMA (LUAD) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC LUNG SQUAMOUS CELL CARCINOMA (LUSC) IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC LARGE CELL CARCINOMA IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC INSTRUMENTS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC SERVICES AND SOFTWARES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC BIOPSY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2020
TABLE 20 ASIA-PACIFIC SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC THORECENTESIS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CLINICAL LABORATORIES IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITAL IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACADEMICS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC INSTITUTES AND RESEARCH CENTERS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 37 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 38 CHINA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 39 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 40 CHINA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 41 CHINA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 42 CHINA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 43 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 45 JAPAN REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 47 JAPAN IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 48 JAPAN MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 49 JAPAN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 50 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 51 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 INDIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 54 INDIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 55 INDIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 56 INDIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 58 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 59 SOUTH KOREA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 60 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 61 SOUTH KOREA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 62 SOUTH KOREA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 63 SOUTH KOREA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 65 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 AUSTRALIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 68 AUSTRALIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 69 AUSTRALIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 70 AUSTRALIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 72 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 MALAYSIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 74 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 75 MALAYSIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 76 MALAYSIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 77 MALAYSIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 79 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 THAILAND REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 81 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 82 THAILAND IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 83 THAILAND MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 84 THAILAND NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 86 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 INDONESIA REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 89 INDONESIA IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 90 INDONESIA MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 91 INDONESIA NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 93 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 94 SINGAPORE REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 96 SINGAPORE IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 97 SINGAPORE MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 98 SINGAPORE NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 100 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 PHILIPPINES REAGENTS AND KITS IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 102 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 103 PHILIPPINES IMAGING TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 104 PHILIPPINES MOLECULAR TEST IN NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2019-2028 (USD MILLION)
TABLE 105 PHILIPPINES NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 106 REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 RISE IN THE GERIATRIC POPULATION THAT IS MORE SUSCEPTIBLE TO NON-SMALL CELL LUNG CANCER IS EXPECTED TO DRIVE THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET
FIGURE 13 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY LUNG CANCER TYPE, 2020
FIGURE 14 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY TEST, 2020
FIGURE 16 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 17 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 18 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 19 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 20 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 21 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: BY LUNG CANCER TYPE (2021 & 2028)
FIGURE 22 ASIA-PACIFIC NON-SMALL CELL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
